CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $638,106 | -15.9% | 23,187 | +3.7% | 0.00% | -20.0% |
| Q2 2023 | $758,777 | -4.7% | 22,363 | +1.1% | 0.01% | 0.0% |
| Q1 2023 | $795,806 | -17.6% | 22,118 | +2.0% | 0.01% | -28.6% |
| Q4 2022 | $966,144 | +57.9% | 21,677 | -0.4% | 0.01% | +75.0% |
| Q3 2022 | $612,000 | +5.9% | 21,756 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $578,000 | -25.7% | 21,449 | -6.1% | 0.00% | 0.0% |
| Q1 2022 | $778,000 | -17.6% | 22,831 | -6.6% | 0.00% | -20.0% |
| Q4 2021 | $944,000 | -30.5% | 24,438 | -2.9% | 0.01% | -28.6% |
| Q3 2021 | $1,359,000 | +84.9% | 25,169 | +14.6% | 0.01% | +250.0% |
| Q2 2021 | $735,000 | – | 21,970 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |